Shots:
- The submission was based on the results from the P-III clinical trials evaluating the equivalence & similarity of CT-P47 vs Actemra (tocilizumab) in patients (n=471) with rheumatoid arthritis (RA)
- Moreover, based on these results the company also expects to accelerate its marketing authorization application across Canada & other countries. The company expects to receive approval by the year 2025
- Actemra is an interleukin inhibitor that functions by reducing inflammation through the inhibition of IL-6 protein
Ref: Celltrion | Image: Celltrion | Press Release
Related News:- Alvotech and Teva’s Simlandi (Biosimilar, Humira) Receives the US FDA’s Approval for the Treatment of Multiple Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
